No Data
No Data
Satellos Bioscience Brief: Announcing Completed Enrollment of All Four Multiple-Ascending Dose Cohorts for Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
Satellos Announces Completed Enrollment of All Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
Satellos Bioscience Raises $57 Million in Public Offering
Satellos Priced US$40 Million Overnight Marketed Public Offering
Satellos Doses First Participant With Duchenne Muscular Dystrophy in Phase 1b Trial